CONMED

CONMED Corp. operates as a medical technology company, which engages in the development, manufacture and sale of surgical devices and related equipment. It operates through the following geographical segments: United States, Americas excluding the United States, Europe, Middle East, and Africa, and Asia Pacific. Its products are used by surgeons and physicians in a variety of medical specialties, including orthopedic surgery, general surgery, gynecology, neurosurgery, thoracic surgery, and gastroenterology. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CONMED faces Q4 challenges, eyes growth through margin improvement

CONMED faced challenges in Q4 due to software implementation issues, resulting in revenue delays and lost opportunities.
Despite this, the company aims for revenue growth and margin improvement, with positive signs in sales recovery and operational stability.
2023 financial guidance shows optimism for growth, with a focus on cost reduction, salesforce retention, and new acquisitions.
Efforts to enhance gross margins and normalize operations present opportunities for profitability and market expansion in the coming years.

CONMED reports strong Q1 performance, focuses on innovation and advocacy

CONMED's Q1 2023 showcased robust sales growth and strategic acquisitions, despite challenges.
The company's focus on innovation, customer recovery, and advocacy positions it well for future success.
Resolving warehouse issues and adapting to potential legislation are key priorities for sustained growth.
Maintaining strong performance amidst challenges highlights CONMED's resilience and market positioning.

CONMED reports robust Q2 growth, eyes market expansion opportunities

CONMED's Q2 performance reflects strong sales growth and improved profitability, particularly in international markets.
The company faces challenges in convincing health systems to adopt pricier procedures and transitioning its sales focus.
Opportunities lie in demonstrating product value, expanding market share, and investing in growth areas like In2Bones and BioBrace.
Overall, CONMED's strategic focus on innovation and market expansion positions it for continued success in the medical device industry.

CONMED reports solid Q3 earnings, anticipates growth despite challenges

CONMED's Q3 performance showed growth in sales and adjusted net income, despite facing supply constraints. The company remains optimistic about future organic growth and expects improvements in margins and FX impact for 2024. Financial stability and strong product performance position CONMED well for future growth.

CONMED reports record revenue in Q4, eyes growth amid challenges

CONMED delivered strong financial performance in Q4 2023, with robust revenue growth and margin improvement, setting optimistic revenue guidance for 2024.
Strategic acquisitions and focus on profitability highlight CONMED's strengths, while challenges like supply disruptions and market dynamics require careful navigation.
Opportunities lie in M&A prospects, BioBrace's growth potential, and differentiation strategies, positioning CONMED for continued success in the medical devices market.

CONMED posts robust Q1 results, adjusts guidance amidst currency impact

CONMED's Q1 results reflect strong financial performance, operational improvements, and strategic leadership changes, setting a positive tone for future growth.
While facing challenges such as currency impacts and guidance adjustments, the company's resilience and commitment to growth remain evident in its revised projections.
With a focus on operational efficiency, market expansion, and maintaining growth momentum, CONMED is poised to navigate challenges and leverage opportunities for sustained success.

CONMED reports Q2 growth, faces Orthopedic supply challenges

CONMED's Q2 performance showed overall growth, with notable strength in the general surgery segment.
Challenges in the Orthopedic side impacted sales and guidance for the year.
The company's focus on cost management and margin improvement is evident in the financial results.
Balancing supply chain issues while capitalizing on general surgery opportunities will be key moving forward.

CONMED reports strong Q3 earnings amidst leadership transition and challenges

CONMED's Q3 performance reflects a resilient financial standing and strategic leadership transition, setting the stage for continued growth.
While challenges like hurricane impacts and supply chain disruptions persist, CONMED's strengths in key segments provide a foundation for future success.
The company's focus on operational efficiency, growth opportunities, and leadership continuity positions CONMED well for sustainable profitability and market expansion.
Navigating challenges and capitalizing on growth opportunities will be crucial for CONMED to drive innovation and maintain its competitive edge in the medical device industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CONMED Corp. is a medical technology company, which engages in providing devices and equipment for surgical procedures. Its products include AirSeal and insufflation, allograft cartilage and tissue, arthroplasty, biliary and endoscopic ultrasound, biomedical sensors and electrodes, biopsy and polypectomy, dilators and accessories, electrosurgical units, fixation devices, hemostasis, implants and suture anchors, infection prevention, patient positioning, and related products. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.

CONMED Corporation (NYSE:CNMD ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Curt Hartman – Chair of the Board, President and Chief Executive Officer Todd Garner – Executive Vice President and Chief Financial Officer Pat Beyer – Chief Operating Officer Conference Call Participants Rick Wise – Stifel Robbie Marcus – JPMorgan Dino Weinstock – Wells Fargo Travis Steed – BofA Mike Matson – Needham Kristen Stewart – CL King Operator Good day, and thank you for standing by. Welcome to CONMED's Second Quarter Fiscal 2024 Earnings Conference Call.

CONMED Corporation (CNMD) Q2 2024 Earnings Call Transcript

Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About Conmed (CNMD) Q2 Earnings

Conmed (CNMD) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.83 per share a year ago.

Conmed (CNMD) Q2 Earnings Beat Estimates

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights Sales of $332.1 million increased 4.5% year-over-year as reported and 5.2% in constant currency. Domestic revenue increased 6.1% year-over-year. International revenue increased 2.6% year-over-year as reported and 4.0% in constant currency. Diluted net earnings per share (GAAP) were $0.96 compared to diluted net earnings per sh.

CONMED Corporation Announces Second Quarter 2024 Financial Results

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Conmed (CNMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced it will report financial results for the second quarter of 2024 after the market close on Wednesday, July 31, 2024. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from.

CONMED Corporation to Announce Second Quarter 2024 Financial Results on July 31, 2024

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

Conmed shares have dropped 30% due to worries about competition from a rival insufflator integrated into Intuitive Surgical's newest daVinci platform. The impact of this competition on Conmed's growth and profitability seems overstated, as robot-attached insufflator revenue would have to decline meaningfully from here to make the math work. Conmed still has multiple growth drivers (including AirSeal), like Buffalo Filter (smoke evacuation), BioBrace bio-inductive implants, and extremity implants, and about 40% of the business is growing at a double-digit rate.

AirSeal Concerns Have Let Too Much Air Out Of Conmed's Valuation

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference at 8:00 a.m. ET on Thursday, June 6, 2024. A live webcast of the fireside chat will be accessible through the “Investors” section of the Company's website at www.conmed.com and will b.

CONMED Corporation to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

Fox Factory Hld

Insulet

Following the so-called “smart money” is often a wise strategy for retail investors. Most individual investors fail to outperform the broader market over the long-run.

Follow the Whales: 3 Genius Stocks the Smart Money Is Piling Into for Triple-Digit Gains

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, Todd W. Garner, Executive Vice President and Chief Financial Officer, and Pat Beyer, Chief Operating Officer, will present at the BofA Securities Healthcare Conference at 2:20 p.m. PT (5:20 p.m. ET) on Tuesday, May 14, 2024 in Las Vegas, NV. A live audio webcast of the presentation will be accessible through the “Investors” section of th.

CONMED Corporation to Present at the BofA Securities Healthcare Conference

CONMED's (CNMD) adjusted first-quarter earnings and revenues beat estimates on the back of strong U.S. and International markets as well as supply-chain improvement.

CONMED (CNMD) Q1 Earnings & Revenues Surpass Estimates

Call End: CONMED Corporation (NYSE:CNMD ) Q1 2024 Earnings Conference Call April 24, 2024, 16:30 PM ET Company Participants Curt Hartman - Chair, President and Chief Executive Officer Todd Garner - Executive Vice President and Chief Financial Officer Conference Call Participants Matt O'Brien - Piper Sandler Young Li - Jefferies Vik Chopra - Wells Fargo Kristen Stewart - CL King Rick Wise - Stifel Robbie Marcus - J.P. Morgan Travis Steed - BofA Securities Mike Matson - Needham Operator Thank you for standing by and welcome to CONMED's First Quarter Fiscal Year 2024 Earnings Conference Call.

CONMED Corporation (CNMD) Q1 2024 Earnings Call Transcript

The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Conmed (CNMD) Reports Q1 Earnings: What Key Metrics Have to Say

Conmed (CNMD) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.66 per share a year ago.

Conmed (CNMD) Surpasses Q1 Earnings and Revenue Estimates

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Patrick Beyer, President of International and Global Orthopedics, has been promoted to the newly created role of Chief Operating Officer (COO), effective immediately. In this role, Mr. Beyer will take on additional responsibility for leading the Company's commercial businesses, as well as Operations, Distribution, Regulatory Affairs / Quality Assurance, and Customer Excellence. “Pat has been invaluable in driving.

CONMED Corporation Promotes Patrick Beyer to Chief Operating Officer

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights Sales of $312.3 million increased 5.7% year-over-year as reported and 5.9% in constant currency. Domestic revenue increased 7.2% year-over-year. International revenue increased 3.8% year-over-year as reported and 4.2% in constant currency. Diluted net earnings per share (GAAP) were $0.63 compared to diluted net earnings per sha.

CONMED Corporation Announces First Quarter 2024 Financial Results

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the first quarter 2024 after the market close on Wednesday, April 24, 2024. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed fro.

CONMED Corporation to Announce First Quarter 2024 Financial Results on April 24, 2024

Starbucks

Despite significant challenges, the U.S. economy has showcased remarkable resilience. Fears of an imminent recession have been allayed by two consecutive quarters of robust GDP growth exceeding 3%.

3 Retirement Stocks to Buy at a 52-Week Low in March

CONMED's (CNMD) adjusted fourth-quarter earnings misses while sales beat estimates on the back of strong growth in the United States and international markets. Gross margin improves with a rise in sales.

CONMED (CNMD) Misses on Q4 Earnings, Beats Revenue Estimates

CONMED Corporation (CNMD) Q4 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here's What Key Metrics Tell Us About Conmed (CNMD) Q4 Earnings

Conmed (CNMD) came out with quarterly earnings of $1.06 per share, missing the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.42 per share a year ago.

Conmed (CNMD) Lags Q4 Earnings and Revenue Estimates

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter 2023 Highlights Sales of $327.0 million increased 30.4% year over year as reported and 31.5% in constant currency Domestic revenue increased 33.3% year over year. International revenue increased 26.5% year over year as reported and 29.0% in constant currency. Diluted net earnings per share (GAAP) were $1.05 compared to dilut.

CONMED Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results

When Utica, NY-based medical technology company CONMED Corporation NYSE: CNMD reports fourth quarter financials after the close on Wednesday, it is expected to post some of its best growth in years.

News for CONMED Stock (CNMD)